GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Earnings per Share (Diluted)

HBPCF (Helix BioPharma) Earnings per Share (Diluted) : $-0.32 (TTM As of Jan. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma Earnings per Share (Diluted)?

Helix BioPharma's Earnings per Share (Diluted) for the three months ended in Jan. 2025 was $-0.10. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 was $-0.32.

Helix BioPharma's EPS (Basic) for the three months ended in Jan. 2025 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2025 was $-0.32.

Helix BioPharma's EPS without NRI for the three months ended in Jan. 2025 was $-0.10. Its EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2025 was $-0.34.


Helix BioPharma Earnings per Share (Diluted) Historical Data

The historical data trend for Helix BioPharma's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Earnings per Share (Diluted) Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.26 -0.24 -0.16 -0.61 -0.77

Helix BioPharma Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.03 -0.08 -0.11 -0.10

Competitive Comparison of Helix BioPharma's Earnings per Share (Diluted)

For the Biotechnology subindustry, Helix BioPharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's PE Ratio falls into.


;
;

Helix BioPharma Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Helix BioPharma's Earnings Per Share (Diluted) for the fiscal year that ended in Jul. 2024 is calculated as

Diluted Earnings Per Share (A: Jul. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-6.755-0)/8.897
=-0.76

Helix BioPharma's Earnings Per Share (Diluted) for the quarter that ended in Jan. 2025 is calculated as

Diluted Earnings Per Share (Q: Jan. 2025 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.956-0)/10.013
=-0.10

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Helix BioPharma  (OTCPK:HBPCF) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Helix BioPharma Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.